Source-grounded facts extracted from TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported quarter ended March 31, 2026 results: revenue Revenues of $4.0 billion, EPS GAAP diluted EPS of $0.31. Guidance reaffirmed.
“Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million”
Chen Lichtenstein was elected as member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“the Board elected Mr. Chen Lichtenstein to serve as a member of the Board, effective December 1, 2024”
Matthew Shields was appointed as Executive Vice President, Global Operations at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Mr. Matthew Shields has been appointed as Executive Vice President, Global Operations of Teva and a member of Teva Executive Management, effective June 3, 2024.”
Eric Drapé departed as Executive Vice President, Global Operations at TEVA PHARMACEUTICAL INDUSTRIES LTD.
“Mr. Eric Drapé, Executive Vice President, Global Operations, will be leaving Teva Pharmaceutical Industries Ltd.”
TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2024 results: revenue $3,819 million, EPS GAAP loss per share of $0.12. Guidance reaffirmed.
“TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO ® growth lead Q1 2024 performance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all regions – increased by 9% in local currency terms globally, compared”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.